Table 8.
Development of methods.
| Subjects | Aim | Results | Ref. no. |
|---|---|---|---|
| Cognition | |||
| Healthy controls, AD | To construct a Swedish version of the National Adult Reading Test (NART-SWE) and to investigate its validity and reliability | The Swedish NART was found to assess premorbid intelligence, even in mild AD | Rolstad et al.55 |
| Healthy controls, MCI, dementia | To evaluate and validate the Cognitive Assessment Battery (CAB) in a specialist clinic setting | CAB was found to differentiate between controls and MCI as well as MCI and dementia with good sensitivity and specificity | Nordlund et al.56 |
| Healthy controls, MCI | To evaluate cognitive profiles in MCI patients with and without vascular burden | CAB found different profiles in MCI with and without vascular burden | Nyström et al.57 |
| Healthy controls MCI, dementia | To examine the reliability and validity of the Cognitive Impairment Questionnaire (CIMP-QUEST) in a specialist clinic setting | CIMP-QUEST was found to have high test–retest reliability and high validity in comparison with psychometric test results | Åstrand et al.54 |
| Healthy controls, SCI | To develop and validate the Sahlgrenska Academy Self-reported Cognitive Impairment Questionnaire (SASCI-Q) in a specialist clinic setting | SASCI-Q was found to discriminate between SCI patients and healthy controls | Eckerström et al.58 |
| Dementia | To develop and validate the Stepwise Comparative Status Analysis (STEP) for identification of symptoms related to brain regions | The STEP instrument was found to identify symptom patterns related to brain regions | Wallin et al.15 |
| Dementia | To investigate the interrater reliability of the STEP protocol | For the majority of variables, the agreement was excellent or moderately good | Edman et al.53 |
| Imaging | |||
| Healthy controls, MCI, dementia | To evaluate three methods (Fazekas rating scale, FreeSurfer, manual volumetry) for the assessment of WMC | Reliability was generally acceptable for all methods but lower in the assessment of small WMC volumes | Olsson et al.59 |
| Neurochemistry | |||
| Healthy controls, AD | To standardize and improve quality of biomarker measurements | Stable quantification obtained for Amyloid beta 1 to 42, phosphorylated tau, and total tau measurements, implementation for clinical routine | Olsson et al.,61 Bjerke et al.,62 Vanderstichele et al.60 |
AD, Alzheimer’s disease; MCI, mild cognitive impairment; SCI, subjective cognitive impairment; WMC, white matter changes.